Heart failure with reduced ejection fraction (HFrEF) requires a multimodal treatment with
combination of several drugs as the cornerstone for symptomatic and prognostic …

Heart failure (HF) is a clinical syndrome with typical symptoms of breathlessness, fatigue,
reduced exercise tolerance, body swelling and signs of fluid retention such as increased …

Four large-scale trials in type 2 diabetes have shown that sodium-glucose cotransporter 2
(SGLT2) inhibitors prevent the occurrence of serious heart failure events. Additionally, the …

The syndrome of heart failure (HF) has historically been dichotomized based on clinical trial
inclusion criteria into patients with a reduced or preserved left ventricular ejection fraction …

Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have recently been recommended as a
foundational therapy for patients with heart failure (HF) and reduced ejection fraction …

Diabetes mellitus intersects with cardiovascular disease at every level. Al-though there has
been much focus on understanding atherosclerotic complications, less well appreciated is …

The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has
recently issued a position paper on the role of sodium–glucose co‐transporter 2 (SGLT2) …

Heart failure (HF) prevalence remains high worldwide with significant sex-related and
regional differences in its presentation, management, and outcomes. In 2020, advances in …

Summary Background Both DAPA-HF (assessing dapagliflozin) and EMPEROR-Reduced
(assessing empagliflozin) trials showed that sodium-glucose co-transporter-2 (SGLT2) …

Importance Additional treatments are needed for heart failure with reduced ejection fraction
(HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment …